Literature DB >> 19458969

LRRK2 and GBA mutations differentially affect the initial presentation of Parkinson disease.

Z Gan-Or1, A Bar-Shira, A Mirelman, T Gurevich, M Kedmi, N Giladi, A Orr-Urtreger.   

Abstract

GBA and LRRK2 mutations increase susceptibility to Parkinson disease (PD), which is characterized by various disabling symptoms. An extended cohort of 600 Ashkenazi PD patients was screened for the LRRK2 G2019S and for eight GBA mutations. Reported initial symptoms were compared between three genotypic groups of patients: carriers of GBA mutations, carriers of LRRK2 G2019S mutation, and non-carriers. More LRRK2 G2019S carriers reported muscle stiffness (rigidity, p = 0.007) and balance disturbances (p = 0.008), while more GBA mutation carriers reported slowness (bradykinesia, p = 0.021). These results suggest distinct effects of LRRK2 or GBA mutations on the initial symptoms of PD.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19458969     DOI: 10.1007/s10048-009-0198-9

Source DB:  PubMed          Journal:  Neurogenetics        ISSN: 1364-6745            Impact factor:   2.660


  20 in total

1.  Clinical phenotype in patients with alpha-synuclein Parkinson's disease living in Greece in comparison with patients with sporadic Parkinson's disease.

Authors:  S Papapetropoulos; C Paschalis; A Athanassiadou; A Papadimitriou; J Ellul; M H Polymeropoulos; T Papapetropoulos
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-05       Impact factor: 10.154

Review 2.  Hematologically important mutations: Gaucher disease.

Authors:  Ernest Beutler; Terri Gelbart; C Ronald Scott
Journal:  Blood Cells Mol Dis       Date:  2005-09-26       Impact factor: 3.039

3.  LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews.

Authors:  Laurie J Ozelius; Geetha Senthil; Rachel Saunders-Pullman; Erin Ohmann; Amanda Deligtisch; Michele Tagliati; Ann L Hunt; Christine Klein; Brian Henick; Susan M Hailpern; Richard B Lipton; Jeannie Soto-Valencia; Neil Risch; Susan B Bressman
Journal:  N Engl J Med       Date:  2006-01-26       Impact factor: 91.245

Review 4.  Emerging pathways in genetic Parkinson's disease: tangles, Lewy bodies and LRRK2.

Authors:  Michael J Devine; Patrick A Lewis
Journal:  FEBS J       Date:  2008-12       Impact factor: 5.542

5.  Is the common LRRK2 G2019S mutation related to dyskinesias in North African Parkinson disease?

Authors:  S Lesage; S Belarbi; A Troiano; C Condroyer; N Hecham; P Pollak; E Lohman; T Benhassine; F Ysmail-Dahlouk; A Dürr; M Tazir; A Brice
Journal:  Neurology       Date:  2008-11-04       Impact factor: 9.910

6.  Mutations in the glucocerebrosidase gene are associated with early-onset Parkinson disease.

Authors:  L N Clark; B M Ross; Y Wang; H Mejia-Santana; J Harris; E D Louis; L J Cote; H Andrews; S Fahn; C Waters; B Ford; S Frucht; R Ottman; K Marder
Journal:  Neurology       Date:  2007-09-18       Impact factor: 9.910

7.  Clinical characteristics of Parkinson's disease among Jewish Ethnic groups in Israel.

Authors:  R Djaldetti; S Hassin-Baer; M J Farrer; C Vilariño-Güell; O A Ross; V Kolianov; S Yust-Katz; T A Treves; Y Barhum; M Hulihan; E Melamed
Journal:  J Neural Transm (Vienna)       Date:  2008-07-30       Impact factor: 3.575

Review 8.  The biology and pathobiology of LRRK2: implications for Parkinson's disease.

Authors:  Darren J Moore
Journal:  Parkinsonism Relat Disord       Date:  2008-07-07       Impact factor: 4.891

9.  A prospective study of familial versus sporadic Parkinson's disease.

Authors:  Spiridon Papapetropoulos; Nikhil Adi; John Ellul; Andreas A Argyriou; Elisabeth Chroni
Journal:  Neurodegener Dis       Date:  2007-10-09       Impact factor: 2.977

Review 10.  Emerging pathways in genetic Parkinson's disease: Potential role of ceramide metabolism in Lewy body disease.

Authors:  Jose Bras; Andrew Singleton; Mark R Cookson; John Hardy
Journal:  FEBS J       Date:  2008-12       Impact factor: 5.542

View more
  35 in total

1.  Gender differences in the risk of familial parkinsonism: beyond LRRK2?

Authors:  R Saunders-Pullman; K Stanley; M San Luciano; M J Barrett; V Shanker; D Raymond; L J Ozelius; S B Bressman
Journal:  Neurosci Lett       Date:  2011-04-12       Impact factor: 3.046

2.  Homozygosity for the MTX1 c.184T>A (p.S63T) alteration modifies the age of onset in GBA-associated Parkinson's disease.

Authors:  Ziv Gan-Or; Anat Bar-Shira; Tanya Gurevich; Nir Giladi; Avi Orr-Urtreger
Journal:  Neurogenetics       Date:  2011-08-12       Impact factor: 2.660

3.  Clinical expression of LRRK2 G2019S mutations in the elderly.

Authors:  Marta San Luciano; Richard B Lipton; Cuiling Wang; Mindy Katz; Molly E Zimmerman; Amy E Sanders; Laurie J Ozelius; Susan B Bressman; Rachel Saunders-Pullman
Journal:  Mov Disord       Date:  2010-11-15       Impact factor: 10.338

Review 4.  The LRRK2 G2019S mutation as the cause of Parkinson's disease in Ashkenazi Jews.

Authors:  Avner Thaler; Elissa Ash; Ziv Gan-Or; Avi Orr-Urtreger; Nir Giladi
Journal:  J Neural Transm (Vienna)       Date:  2009-11       Impact factor: 3.575

5.  Neuropsychiatric characteristics of GBA-associated Parkinson disease.

Authors:  Matthew Swan; Nancy Doan; Robert A Ortega; Matthew Barrett; William Nichols; Laurie Ozelius; Jeannie Soto-Valencia; Sarah Boschung; Andres Deik; Harini Sarva; Jose Cabassa; Brooke Johannes; Deborah Raymond; Karen Marder; Nir Giladi; Joan Miravite; William Severt; Rivka Sachdev; Vicki Shanker; Susan Bressman; Rachel Saunders-Pullman
Journal:  J Neurol Sci       Date:  2016-08-30       Impact factor: 3.181

6.  Genetic markers of Restless Legs Syndrome in Parkinson disease.

Authors:  Ziv Gan-Or; Roy N Alcalay; Anat Bar-Shira; Claire S Leblond; Ronald B Postuma; Shay Ben-Shachar; Cheryl Waters; Amelie Johnson; Oren Levy; Anat Mirelman; Mali Gana-Weisz; Nicolas Dupré; Jacques Montplaisir; Nir Giladi; Stanley Fahn; Lan Xiong; Patrick A Dion; Avi Orr-Urtreger; Guy A Rouleau
Journal:  Parkinsonism Relat Disord       Date:  2015-03-17       Impact factor: 4.891

7.  Higher frequency of certain cancers in LRRK2 G2019S mutation carriers with Parkinson disease: a pooled analysis.

Authors:  Ilir Agalliu; Marta San Luciano; Anat Mirelman; Nir Giladi; Bjorg Waro; Jan Aasly; Rivka Inzelberg; Sharon Hassin-Baer; Eitan Friedman; Javier Ruiz-Martinez; Jose Felix Marti-Masso; Avi Orr-Urtreger; Susan Bressman; Rachel Saunders-Pullman
Journal:  JAMA Neurol       Date:  2015-01       Impact factor: 18.302

Review 8.  Genetic convergence of Parkinson's disease and lysosomal storage disorders.

Authors:  Hao Deng; Xiaofei Xiu; Joseph Jankovic
Journal:  Mol Neurobiol       Date:  2014-08-07       Impact factor: 5.590

9.  The p.L302P mutation in the lysosomal enzyme gene SMPD1 is a risk factor for Parkinson disease.

Authors:  Ziv Gan-Or; Laurie J Ozelius; Anat Bar-Shira; Rachel Saunders-Pullman; Anat Mirelman; Ruth Kornreich; Mali Gana-Weisz; Deborah Raymond; Liron Rozenkrantz; Andres Deik; Tanya Gurevich; Susan J Gross; Nicole Schreiber-Agus; Nir Giladi; Susan B Bressman; Avi Orr-Urtreger
Journal:  Neurology       Date:  2013-03-27       Impact factor: 9.910

10.  Transcranial sonography and functional imaging in glucocerebrosidase mutation Parkinson disease.

Authors:  M J Barrett; J Hagenah; V Dhawan; S Peng; K Stanley; D Raymond; A Deik; S J Gross; N Schreiber-Agus; A Mirelman; K Marder; L J Ozelius; D Eidelberg; S B Bressman; R Saunders-Pullman
Journal:  Parkinsonism Relat Disord       Date:  2012-10-10       Impact factor: 4.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.